Investor Presentation - Broker Meets Biotech
Filed with ASX · · 14 pages · English
Summary by 6ix AI
The presentation outlines the accelerated development pathway and the advantages of their proprietary injectable formulation compared to traditional treatments. The document also discusses the clinical development timeline and key milestones expected in the near future.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Story so far
Earlier from Patrys
- RLS-2201 Manufacturing and Regulatory Pathway Initiated
- Appendix 4D - Half Year Accounts - 31 December 2025
- Appointment of Chief Executive Officer
- Appendix 4C - Quarterly - 31 December 2025
- Investor Presentation
Later from Patrys
- $3.2 million Placement to Advance Clinical Trials
- Appendix 4C - Quarterly - 31 March 2026
- Patrys advances RLS-2202 toward Phase 1 Clinical Trial
- Patrys Secures 50% Revenue Share in IP Commercialisation
- Appendix 4C - Quarterly - 30 June 2026
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys